NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 5 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Zydus Wellness Q2 FY27 Call: Net Sales Up 74.6% YoY to ₹1,122.7 Cr, EBITDA Jumps 271.7%
Zydus Wellness submitted its Q2 FY27 earnings call transcript, highlighting consolidated net sales of ₹1,122.7 crore (up 74.6% YoY) and H1 FY27 net sales of ₹2,552.6 crore (up 70.1% YoY). Consolidated EBITDA for the quarter rose 271.7% YoY to ₹85.5 crore, supported by gross margin expansion and consolidation of Comfort Click. The domestic portfolio grew 29.2% YoY, led by a 123.5% rebound in seasonal brands and 37.5% growth in skin and hair care. Management highlighted moderating like-to-like growth in Comfort Click to 12.4% during Q2 (18.6% in H1) due to web migration and higher competition, while Complan maintained its positive momentum for three consecutive quarters.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the verbatim transcript for the Q2 FY27 earnings conference call held on November 3, 2026.
ஏன் இது முக்கியம்Provides detailed qualitative and segment-level context on the integration and margin dynamics of Comfort Click, as well as the turnaround initiatives in Complan.
Q2 FY27 Net Sales: INR 11,227 millionQ2 Net Sales YoY Growth: 74.6%Q2 FY27 EBITDA: INR 855 millionQ2 EBITDA YoY Growth: 271.7%H1 FY27 Net Sales: INR 25,526 millionH1 FY27 EBITDA: INR 3,272 million
📅 குறுகிய காலம்Transcript reveals operational details; post-earnings price reactions have already factored in Q2 headline numbers, but commentary clarifies Comfort Click's competitive landscape.
📈 நீண்ட காலம்Success depends on diversifying away from summer seasonality (Glucon-D/Nycil) through international nutraceuticals (Comfort Click) and maintaining market share in health food drinks (Complan).
⚠ அபாய எச்சரிக்கைகள்
Competitive intensity increasing in Comfort Click's key international VMS markets
High structural seasonality with summer products
👀 கவனிக்க வேண்டியவை
Track whether Comfort Click's like-to-like growth re-accelerates beyond 12.4% following marketing ramp-ups, and monitor sustainability of Complan's double-digit trajectory over coming quarters.
Zydus Wellness Q2 Net Sales Up 74.6% to ₹1,123 Cr; EBITDA Surges 271.7%
Zydus Wellness reported a 74.6% YoY jump in consolidated net sales to ₹1,122.7 crore (₹11,227 million) for Q2 FY27, up from ₹642.9 crore a year prior. Operating profitability improved significantly, with EBITDA surging 271.7% YoY to ₹85.5 crore (₹855 million). For H1 FY27, net sales rose 70.1% to ₹2,552.6 crore while EBITDA grew 83.2% to ₹327.2 crore. Performance was aided by double-digit growth in Everyuth, Sugar Free, RiteBite Max Protein, and Complan.
உச்சம் நம்பிக்கை
என்ன மாறியதுZydus Wellness announced its Q2 FY27 press release showing sharp top-line acceleration (+74.6%) and operational turnaround with EBITDA jumping over 270%.
ஏன் இது முக்கியம்The company has historically struggled with off-season H1 profitability; strong Q2 EBITDA indicates successful integration of acquisitions (RiteBite, Comfort Click) and healthy core brand traction.
Q2 Net Sales: ₹11,227 millionQ2 Net Sales Growth: 74.6%Q2 EBITDA: ₹855 millionQ2 EBITDA Growth: 271.7%H1 Net Sales: ₹25,526 millionSugar Free Market Share: 96%
📅 குறுகிய காலம்Earnings sentiment should be supported in the near term by robust top-line growth and substantial margin recovery in what is typically a weaker quarter.
📈 நீண்ட காலம்Portfolio diversification into protein snacking and health supplements helps reduce dependence on seasonal brands (Glucon-D, Nycil), improving annual cash flow consistency.
⚠ அபாய எச்சரிக்கைகள்
Net profit (PAT) figures were not stated in the press release extract
Commodity cost headwinds noted in spreads portfolio (Nutralite)
👀 கவனிக்க வேண்டியவை
Track the upcoming detailed financial results filing for bottom-line PAT figures and monitor how off-season brand diversification mitigates historical summer-heavy revenue seasonality.
Zydus Wellness Q2 Standalone PAT Rises 53% YoY to ₹11.6 Cr; Revenue Up 7% to ₹166.8 Cr
Zydus Wellness reported its Q2 (quarter ended September 30, 2026) standalone revenue from operations of ₹166.8 crore (₹1,668 million), up 6.9% YoY compared to ₹156.0 crore in Q2 FY26. Standalone net profit for the quarter rose 52.6% YoY to ₹11.6 crore (₹116 million) from ₹7.6 crore, aided by an absence of exceptional items (which was ₹9.7 crore in Q2 FY26). For the half year (H1 FY27), consolidated cash flow from operating activities improved sharply to ₹312.1 crore (₹3,121 million) compared to ₹93.1 crore in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுZydus Wellness approved and declared its standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026.
ஏன் இது முக்கியம்The company demonstrated sequential and YoY standalone profit expansion and strong H1 operating cash flow generation (₹312.1 crore), supporting balance sheet liquidity.
Standalone Q2 Revenue: ₹166.8 கோடிStandalone Q2 Net Profit: ₹11.6 கோடிStandalone H1 Revenue: ₹319.8 கோடிStandalone H1 Net Profit: ₹17.1 கோடிConsolidated H1 Operating Cash Flow: ₹312.1 கோடி
📅 குறுகிய காலம்Stable Q2 standalone figures and improved operating cash flows could provide near-term sentiment support following a period of stock consolidation.
📈 நீண்ட காலம்Long-term trajectory hinges on managing extreme summer seasonality (70% revenue dependency in H1/summer), scaling distribution to 3.5 million outlets, and turning around Complan margins.
⚠ அபாய எச்சரிக்கைகள்
High seasonality risk with historically weaker winter quarters
Raw material cost pressures (cost of materials consumed rose to ₹116.6 cr vs ₹85.1 cr YoY)
👀 கவனிக்க வேண்டியவை
Track the full consolidated segmental performance and margins across key brands like Complan, Glucon-D, and Nycil as the company heads into the seasonally weaker H2 before the summer peak.
Zydus Wellness Limited has appointed Mr. Kapil Sharma as Chief Revenue Officer (India and Indian subcontinent), effective September 1, 2026. Mr. Sharma brings over 28 years of commercial and sales experience, including 25 years at Procter & Gamble (P&G), where he recently served as VP-Gillette for the subcontinent. The appointment comes as the company seeks to expand its direct retail distribution reach to 3.5 million outlets and scale its ₹1,947 Cr TTM revenue base.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Kapil Sharma has taken charge as Chief Revenue Officer (India & Indian subcontinent) as part of Zydus Wellness's Senior Management.
ஏன் இது முக்கியம்Adds high-caliber consumer goods leadership to steer domestic sales, direct-to-consumer strategy, and distribution growth across key brands like Complan, Glucon-D, and Nycil.
Effective Date: செப்டம்பர் 1, 2026Total Professional Experience: 28+ yearsP&G Tenure: 25 yearsTTM Revenue Base: ₹1947 கோடி
📅 குறுகிய காலம்Operational transition with no immediate financial impact; positive sentiment for strengthening commercial leadership.
📈 நீண்ட காலம்Supports the company's long-term target of widening direct distribution reach and improving product monetization across seasonal and non-seasonal portfolios.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in competitive FMCG health food drinks and personal care categories
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly revenue execution, distribution footprint expansion, and strategies to address the company's seasonal revenue skew.
66.7% Revenue Growth in Q1 FY27; Digital Sales Reach 21% Saliency
Zydus Wellness reported a significant 66.7% YoY increase in consolidated net sales to ₹1,429.9 cr for Q1 FY27, primarily driven by the integration of the Comfort Click acquisition. While the international business grew 24.8% like-for-like, domestic growth was a modest 4.6% as seasonal brands (Nycil, Glucon-D) declined by 12% due to unseasonal rainfall. EBITDA rose 55.3% to ₹241.7 cr, although reported net profit fell 7% due to brand amortization costs. The company is successfully pivoting to digital channels, with digital commerce now accounting for 21% of total sales.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has significantly scaled its international and digital footprint, reducing its historical 70% revenue dependency on the Indian summer season.
ஏன் இது முக்கியம்The massive revenue jump validates the Comfort Click acquisition strategy, while the 21% digital saliency indicates a successful shift toward premium, high-growth distribution channels.
Q1 FY27 Net Sales: ₹1,429.9 கோடிYoY Revenue Growth: 66.7%EBITDA Growth: 55.3%Digital Commerce Saliency: 21%A&P Spend as % of Sales: 18.2%Domestic Business Growth: 4.6%
📅 குறுகிய காலம்The strong top-line and EBITDA growth are likely to be viewed positively, though the reported PAT decline due to amortization may require investor education on cash vs. accounting profits.
📈 நீண்ட காலம்The structural shift toward a diversified, digital-first portfolio reduces seasonal volatility and improves the long-term margin profile through premiumization.
⚠ அபாய எச்சரிக்கைகள்
High seasonality risk (weather-sensitive brands)
Brand amortization impacting reported net profit
Intense competition in the Health Food Drink (Complan) segment
👀 கவனிக்க வேண்டியவை
Monitor the performance of seasonal brands in the next summer cycle and the continued margin contribution from the Comfort Click acquisition. Investors should focus on 'Cash PAT' (up 26.5%) rather than reported PAT to account for non-cash brand amortization.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
66.7% Net Sales Growth in Q1 FY27; EBITDA up 55.3% to ₹241.7 Cr
Zydus Wellness reported a strong Q1 FY27 with consolidated net sales reaching ₹1,429.9 Cr, a 66.7% increase from ₹857.7 Cr in the previous year. EBITDA grew by 55.3% to ₹241.7 Cr, while net profit for the quarter stood at ₹118.9 Cr. The company maintained dominant market leadership in key categories, including a 96.1% share in sugar substitutes and 59.1% in energy drinks. Strategic expansions included entering the Walmart Marketplace in the USA and launching new products like Complan Power Play and VieMax Diabetes Care.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company delivered a significant YoY jump in revenue and EBITDA, driven by market share gains and the integration of new brands like Comfort Click.
ஏன் இது முக்கியம்Q1 is the most critical quarter for Zydus Wellness due to the high seasonality of Glucon-D and Nycil; this strong performance provides a solid base for FY27 growth targets.
Net Sales (Q1 FY27): ₹1,429.9 கோடிYoY Sales Growth: 66.7%EBITDA: ₹241.7 கோடிநிகர லாபம்: ₹118.9 கோடிSugar Free Market Share: 96.1%Q1 வருவாய் vs TTM வருவாய்: 76.01%
📅 குறுகிய காலம்The stock is likely to react positively to the high double-digit revenue and EBITDA growth, confirming strong execution during the peak summer season.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to scale Complan and new nutrition launches to balance its seasonal revenue skew and improve its ROCE from the current 2%.
⚠ அபாய எச்சரிக்கைகள்
High seasonality (70% revenue from summer products)
Intense competition in the Health Food Drink segment
Low historical ROCE of 2.0%
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of new launches in the diabetes care and ready-to-drink segments to see if they can reduce the company's 70% revenue dependence on the summer season. Watch for the impact of international DTC expansion on overall margins in upcoming quarters.
66.7% Revenue Growth in Q1 FY27; Adjusted PAT up 26.5% Following Comfort Click Integration
Zydus Wellness reported a sharp 66.7% YoY increase in Net Sales to ₹1,429.9 crore for Q1 FY27, primarily driven by the consolidation of the Comfort Click acquisition. While reported PAT declined 7% to ₹118.9 crore due to a 920% surge in brand amortization (₹49 crore), adjusted net profit grew 26.5% to ₹167.9 crore. The core portfolio remains dominant with Sugar Free holding a 96.1% market share, though seasonal brands like Glucon-D saw flattish growth due to unseasonal rains in North and East India.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully consolidated the Comfort Click acquisition, leading to a step-change in revenue scale and a significant increase in non-cash amortization expenses.
ஏன் இது முக்கியம்The acquisition significantly expands Zydus Wellness's international footprint and digital presence, though the high amortization will continue to weigh on reported PAT while adjusted cash profits remain healthy.
Q1 FY27 Net Sales: ₹1,429.9 கோடிQ1 Sales vs TTM Revenue: 76.01%Adjusted Net Profit Growth: 26.5%Sugar Free Market Share: 96.1%Amortization Expense (Q1): ₹49.0 கோடி
📅 குறுகிய காலம்The market is likely to react positively to the massive top-line growth and adjusted profit expansion, despite the accounting-led dip in reported PAT.
📈 நீண்ட காலம்The shift towards a more diversified, less seasonal portfolio through acquisitions is structurally positive, though improving the low ROCE (2.0%) remains a long-term challenge.
⚠ அபாய எச்சரிக்கைகள்
High seasonality (70% revenue skew towards summer months)
👀 கவனிக்க வேண்டியவை
Watch for the stabilization of margins as the Comfort Click acquisition integrates and monitor if the company can sustain double-digit growth in the 'Sugar Free' and 'Everyuth' segments to offset seasonality in Glucon-D.
Zydus Wellness Q1 Standalone Revenue Up 8.6% YoY to ₹153 Cr; Net Profit at ₹5.5 Cr
Zydus Wellness reported standalone revenue of ₹153 crore for Q1 FY27 (ended June 30, 2026), marking an 8.6% growth over the ₹140.9 crore reported in the same quarter last year. Standalone net profit rose 19.6% YoY to ₹5.5 crore, although it saw a sequential decline from the ₹13.3 crore earned in the March 2026 quarter. The results highlight the company's extreme seasonality, with performance heavily dependent on summer-centric brands. The standalone business represents approximately 31% of the group's TTM consolidated revenue, with the remainder driven by subsidiaries including the recently acquired Comfort Click Limited.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its unaudited standalone and consolidated financial results for the first quarter of the 2026-27 fiscal year, showing modest growth in its standalone operations.
ஏன் இது முக்கியம்Q1 is a seasonally significant period for Zydus Wellness due to its summer-heavy product mix (Glucon-D, Nycil); these results provide an early indicator of the year's performance trajectory and the health of its standalone consumer business.
Standalone Revenue (Q1): 1,530 MillionStandalone Net Profit (Q1): 55 MillionMaterial Cost as % of Revenue: 66.7%Comfort Click Acquisition Cost: GBP 239 millionStandalone Q1 Revenue vs TTM Consolidated Revenue: ~8.1%
📅 குறுகிய காலம்The stock is likely to remain neutral in the short term as the standalone growth is modest and the market awaits full consolidated details on the international business integration.
📈 நீண்ட காலம்Long-term value depends on the successful integration of international acquisitions and the ability to scale non-seasonal brands like RiteBite and Complan to balance the revenue skew.
⚠ அபாய எச்சரிக்கைகள்
High seasonality (70% revenue in summer months)
High raw material cost concentration (66.7% of standalone revenue)
Integration risks associated with the large GBP 239 million UK acquisition
👀 கவனிக்க வேண்டியவை
Investors should monitor the consolidated financial performance to gauge the full impact of the Comfort Click acquisition and track the company's progress in reducing its 70% revenue dependency on the summer season.
Zydus Wellness Appoints Dr. Shyam Ramakrishnan as Chief Scientific Officer Effective July 1, 2026
Zydus Wellness has appointed Dr. Shyam Ramakrishnan as Chief Scientific Officer (CSO) and part of the Senior Management, effective July 1, 2026. Dr. Ramakrishnan brings over 25 years of experience in nutrition, dietary supplements, and functional foods, having held leadership roles at Amway, ITC, and The Himalaya Drug Company. This strategic hire is significant as the company seeks to diversify its portfolio beyond its current 70% revenue dependency on seasonal summer products like Glucon-D and Nycil. With a TTM revenue of ₹1,881 Cr and a high P/E of 70.8, the market will look for R&D-led innovation to drive growth and improve the current 2.0% ROCE.
உச்சம் நம்பிக்கை
என்ன மாறியதுZydus Wellness has added a high-profile Chief Scientific Officer to its senior management team to lead innovation and R&D.
ஏன் இது முக்கியம்The company needs to innovate to justify its high valuation (70.8 P/E) and to balance its portfolio, which currently relies on seasonal products for 70% of its annual revenue.
📅 குறுகிய காலம்The announcement is unlikely to impact the stock price immediately as the appointment is effective from July 2026, but it signals a long-term commitment to R&D.
📈 நீண்ட காலம்Crucial for structural growth; a strong R&D head can help the company transition into a year-round wellness player and improve low capital efficiency (2.0% ROCE).
⚠ அபாய எச்சரிக்கைகள்
Execution risk in new product categories
High revenue concentration in summer months (70%)
👀 கவனிக்க வேண்டியவை
Monitor the company's R&D pipeline and the launch of new functional food variants over the next 4-6 quarters to see if the new leadership can effectively reduce seasonal revenue volatility.
Zydus Wellness Incorporates New Step-Down Subsidiary in Dubai for UAE Expansion
Zydus Wellness Limited has announced the incorporation of a new step-down wholly owned subsidiary, Zydus Wellness Trading L.L.C. (ZWTL), in Dubai, UAE. The entity was formed through its subsidiary Zydus Wellness International DMCC with a share capital of AED 300,000. This move is aimed at expanding the company's international footprint in the Food and Nutrition, Nutraceuticals, and Personal Care segments. While the entity has nil turnover currently, it represents a strategic move to capture market share in the Middle East.
முக்கிய அம்சங்கள்
Incorporation of Zydus Wellness Trading L.L.C. (ZWTL) as a 100% step-down subsidiary in Dubai.Initial share capital of AED 300,000 divided into 300 shares of AED 1,000 each.Focus sectors include Food and Nutrition, Nutraceuticals, and Personal Care products.The subsidiary is a 100% owned entity of Zydus Wellness International DMCC, UAE.The move is specifically designated for business expansion in the UAE market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term strategic step to diversify geographic revenue; monitor future quarterly reports for updates on international revenue contribution.
Zydus Wellness Incorporates Step-Down Subsidiary in Ireland for VMS Expansion
Zydus Wellness has announced the incorporation of a new step-down wholly owned subsidiary, Zydus Wellness (EU) Limited, in Ireland. The entity was established through the company's UAE-based subsidiary, Zydus Wellness International DMCC, which holds 100% of the share capital. This move is aimed at business expansion within the Vitamins, Minerals, and Supplements (VMS) industry. While the initial capital is nominal at €100, it marks a strategic entry into the European market.
முக்கிய அம்சங்கள்
Incorporation of Zydus Wellness (EU) Limited in Ireland on June 23, 2026100% ownership held by UAE-based subsidiary Zydus Wellness International DMCCInitial share capital of €100 consisting of 100 ordinary shares of €1 eachFocus on the Vitamins, Minerals and Supplements (VMS) business segmentEntity is a newly incorporated unit with operations yet to commence
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term strategic move to capture the European VMS market. Monitor future quarterly updates for capital allocation and revenue contributions from this new geography.
Zydus Wellness Q4 FY26: Net Sales Surge 62.1% Driven by International Growth and Acquisitions
Zydus Wellness reported a robust 62.1% growth in net sales for Q4 FY26, primarily fueled by the international business and the Comfort Click acquisition. While the domestic business saw a modest 1.7% growth, skin and hair care brands outperformed with a 39.7% increase. EBITDA grew by 42.2% to INR 2,701 million, although reported net profit declined due to acquisition-related finance costs and amortization. Adjusted net profit, excluding exceptional items, showed a healthy 17% growth for the quarter.
முக்கிய அம்சங்கள்
Net sales grew 62.1% YoY in Q4 FY26, with full-year EBITDA reaching INR 5,097 million.International business delivered 31.4% like-to-like growth, while domestic seasonal brands declined 9.8% due to unseasonal rains.Organized channel saliency (E-commerce and Modern Trade) improved to 30% from 24% in the previous year.Sugar Free market share expanded by 24 basis points, and Sugar Free Green recorded its 20th consecutive quarter of double-digit growth.Adjusted net profit (excluding amortization and exceptional items) grew 17% YoY for the quarter.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of high-margin seasonal brands like Glucon-D in the upcoming quarters and the stabilization of finance costs following the recent acquisition. The strong growth in the international segment and digital-first brands provides a positive long-term outlook despite short-term domestic headwinds.
Zydus Wellness Recommends ₹1.20 Dividend; Sets Record Date for July 17, 2026
Zydus Wellness has recommended a final dividend of ₹1.20 per equity share (60% of face value) for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine eligible shareholders, with payments starting from August 7, 2026. Additionally, the board has appointed Mr. Apurva S. Diwanji, a legal and M&A veteran, as an Independent Director for a five-year term. The 32nd Annual General Meeting is scheduled for August 4, 2026, to seek shareholder approval for these proposals.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹1.20 per share (60% of ₹2 face value)Record date for dividend entitlement is fixed as July 17, 2026Appointment of Mr. Apurva S. Diwanji as Independent Director for a 5-year termDividend payment to commence on or after August 7, 2026, post-AGM approval32nd Annual General Meeting scheduled for August 4, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the July 17 record date. The addition of a legal and M&A expert to the board is a positive step for corporate governance and strategic oversight.
Zydus Wellness Q4 Net Sales Surges 62.1% to Rs 14,761 Million; FY26 Sales Up 46.4%
Zydus Wellness reported a robust performance for Q4 FY26 with net sales growing 62.1% YoY to Rs 14,761 million, while annual sales reached Rs 39,400 million. The company's EBITDA grew by 34.2% to Rs 5,097 million, reflecting the successful integration of its newly acquired business and strong organic growth. Key brands like Sugar Free and Glucon-D maintained dominant market shares of 96.1% and 58.9% respectively. The RiteBite Max Protein business showed significant margin improvement, moving from breakeven to near double-digit margins within a year of acquisition.
முக்கிய அம்சங்கள்
Net Sales for Q4 FY26 grew by 62.1% YoY to Rs 14,761 million, while FY26 sales rose 46.4% to Rs 39,400 million.EBITDA for the period stood at Rs 5,097 million, marking a 34.2% YoY growth including post-acquisition performance.Sugar Free maintains a near-monopoly with 96.1% market share, while Glucon-D leads the category with 58.9% share.RiteBite Max Protein business improved from breakeven at acquisition to near double-digit EBITDA margins.Everyuth leads the scrub category with 48.6% share and peel-off masks with 75.5% share, delivering strong double-digit growth.
👀 கவனிக்க வேண்டியவை
Investors should note the strong top-line momentum and the successful margin expansion in the recently acquired protein business. The company's dominant market share across multiple wellness categories makes it a strong play in the FMCG-Healthcare hybrid space.
Zydus Wellness demonstrated strong market dominance in Q4 FY26, with its flagship brand Sugar Free maintaining a 96.1% market share. The company reported a significant recovery in Complan, which achieved near double-digit growth despite a 4.8% decline in the overall category. Strategic expansion into the protein snacking segment via Max Protein is yielding results, with the brand reaching nearly double-digit EBITDA margins. Additionally, the company strengthened its balance sheet by repurchasing ₹15,000 million in NCDs following a ₹10,000 million capital raise.
முக்கிய அம்சங்கள்
Sugar Free maintains a dominant 96.1% market share, with Sugar Free Green delivering 20 consecutive quarters of double-digit growth.Complan outperformed its category by growing near double-digits while the broader market segment declined by 4.8%.Everyuth brand reached an 8.0% share in facial cleansing, ranking 4th in the JFM'26 quarter, with leadership in scrubs (48.6%) and peel-off masks (75.5%).Max Protein portfolio successfully transitioned from break-even to nearly double-digit EBITDA margins due to operating leverage.Completed a ₹10,000 million capital restructure and repurchased ₹15,000 million of NCDs to optimize the balance sheet.
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustained recovery in Complan and the scaling of the Max Protein segment as primary growth catalysts. The company's ability to maintain near-monopoly shares in core categories while reducing debt makes it a strong play in the FMCG wellness space.
Zydus Wellness Recommends ₹1.20 Dividend and Appoints Apurva Diwanji as Independent Director
Zydus Wellness has recommended a final dividend of ₹1.20 per equity share (60% of face value) for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine eligibility for the dividend payment, which is expected to commence on or after August 7, 2026. Additionally, the board has appointed Mr. Apurva S. Diwanji as an Independent Director for a five-year term. Mr. Diwanji is a legal veteran with over 32 years of experience in M&A and corporate governance, having previously served on the board of Zydus Lifesciences.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.20 per equity share of ₹2 each (60% payout).Fixed July 17, 2026, as the record date for dividend entitlement.Appointed Mr. Apurva S. Diwanji as an Independent Director for a 5-year term until May 2031.Mr. Diwanji brings 32+ years of expertise in M&A, private equity, and corporate law.The 32nd Annual General Meeting is scheduled for August 4, 2026.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the July 17 record date. The addition of a seasoned legal and M&A expert to the board is a positive signal for corporate governance and strategic oversight.
Zydus Wellness Recommends Final Dividend of ₹1.20 Per Share for FY26
Zydus Wellness Limited has recommended a final dividend of ₹1.20 per equity share for the financial year ended March 31, 2026. This represents a 60% payout on the face value of ₹2 per share. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for August 4, 2026. The company also confirmed that its statutory auditors have issued an unmodified opinion on the audited financial results for the year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.20 per equity share of ₹2 face valueDividend payout represents 60% of the face value of the sharesAnnual General Meeting for dividend approval is scheduled for August 4, 2026Statutory auditors Mukesh M. Shah & Co. submitted an unmodified audit report for FY26
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend yield should monitor for the announcement of the record date. The recommendation reflects the company's commitment to returning value to shareholders following the completion of the fiscal year.
Zydus Wellness Q3 Net Sales Surge 113.7% to ₹9,633 Mn Driven by Comfort Click Acquisition
Zydus Wellness reported a massive 113.7% YoY increase in Q3 FY26 Net Sales to ₹9,633 million, primarily driven by the strategic acquisition of Comfort Click. While Gross Margins expanded significantly by 1561 bps to 63.3%, the company reported a PAT loss of ₹399 million for the quarter due to high finance costs of ₹371 million and brand amortization of ₹472 million related to the acquisition. Core brands like Sugar Free and Glucon-D continue to maintain dominant market leadership with 96.3% and 59% shares respectively, while the RiteBite business has doubled its legacy performance.
முக்கிய அம்சங்கள்
Q3 FY26 Net Sales grew 113.7% YoY to ₹9,633 million; YTD FY26 sales reached ₹24,639 million.Gross Margin for Q3 FY26 improved by 1561 bps YoY to 63.3%, supported by newly acquired high-margin brands.Reported a Q3 PAT loss of ₹399 million, impacted by acquisition-related interest and non-cash amortization expenses.Sugar Free maintains a dominant 96.3% market share, while Everyuth Peel-off leads its category with 76% share.Distribution network expanded to 2.8 million total stores with a direct reach of 0.7 million outlets.
👀 கவனிக்க வேண்டியவை
Investors should look past the headline PAT loss which is skewed by one-time acquisition costs and non-cash amortization; focus instead on the robust EBITDA growth and massive gross margin expansion. Monitor the company's ability to deleverage the bridge loan used for the acquisition to improve bottom-line profitability in coming quarters.
Zydus Wellness reported a massive 113.7% YoY increase in Q3 FY26 net sales to ₹9,633 million, primarily driven by the integration of the newly acquired Comfort Click and RiteBite businesses. Gross margins saw a significant expansion of 1561 bps to 63.3%, although the company reported a net loss of ₹399 million for the quarter due to high finance costs and amortization related to acquisitions. The company maintains dominant market leadership in core categories, with Sugar Free holding a 96.3% share and Glucon-D at 59.0%. Strategic capital restructuring was completed with a ₹10,000 million fundraise and ₹15,000 million NCD repurchase to optimize the balance sheet.
முக்கிய அம்சங்கள்
Net Sales for Q3 FY26 surged 113.7% YoY to ₹9,633 million, while YTD FY26 sales grew 38.4% to ₹24,639 million.Gross Margin expanded to 63.3% in Q3 FY26, up from 47.7% in the previous year, supported by new high-margin brands.Sugar Free remains the market leader with a 96.3% share, while Everyuth Peel-off and Scrub hold 76.0% and 48.5% shares respectively.EBITDA for Q3 FY26 grew by 312.2% YoY to ₹610 million, despite bottom-line pressure from ₹371 million in finance costs.Completed acquisition of Comfort Click Limited, adding international brands like WeightWorld and maxmedix to the portfolio.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to transition the high revenue growth into net profitability as acquisition-related interest and amortization costs stabilize. The strong market share in core brands provides a solid foundation, but the performance of the international VMS segment will be the primary driver for future re-rating.
Zydus Wellness Q3 FY26 Net Sales Surge 113.7% Driven by Comfort Click Acquisition
Zydus Wellness reported a massive 113.7% YoY increase in net sales for Q3 FY26, primarily fueled by the integration of the Comfort Click acquisition. While the company reported a net loss of INR 399 million due to high amortization and interest costs from the acquisition, EBITDA grew by 312.2% to INR 610 million. Gross margins expanded significantly to 63% as the new business operates at higher margins, with management targeting 66-67% on an annualized basis. The RiteBite business also showed strong momentum, doubling its legacy performance and nearing double-digit EBITDA margins.
முக்கிய அம்சங்கள்
Net sales grew 113.7% YoY, with the Food & Nutrition segment surging 134%EBITDA increased by 312.2% YoY to INR 610 million, with margins expanding to 6.3%Gross margins reached 63% due to the high-margin Comfort Click portfolio mixReported a net loss of INR 399 million after accounting for INR 472 million in brand amortization and INR 371 million in interestRiteBite Max Protein business doubled its legacy performance and is approaching double-digit margins
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong operational growth and margin expansion post-acquisition, while monitoring the deleveraging process and the impact of non-cash amortization on reported profits.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
